stockrow
Friday 6 November 2026
Export KYMR’s income statement to Excel — free account
Kymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
132.01
3.89
+3.04%
Follow KYMR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
167.66 | 157.81 | 107.22 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(98.49) | (91.44) | (208.23) | — | |
P/B ratio |
4.16 | 5.28 | 7.46 | — | |
Price to Tangible BV |
4.16 | 5.28 | 7.46 | — | |
EV/Sales |
146.07 | 145.19 | 100.65 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(24.59) | (30.81) | (44.63) | — | |
EV/FCF |
(24.44) | (30.63) | (44.41) | — | |
Quick Ratio |
10.19 | 10.39 | 9.97 | 10.82 | |
Current Ratio |
10.47 | 10.81 | 10.34 | 11.13 | |
Net Debt/EBITDA |
8.65 | 7.66 | 9.09 | 6.61 | |
Debt/Assets |
0.08% | 0.07% | 0.05% | 0.03% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.04 | 0.08 | 0.00 | |
Operating CF/Net income |
0.77 | 1.28 | 0.88 | 0.59 | |
Capex/Depreciation |
8.15 | 0.61 | 1.59 | (0.76) | |
Interest Coverage |
(1,064.08) | (1,379.57) | (933.42) | (2,374.71) | |
Research and Development Expense of Revenue |
2,919.92% | 285.65% | 183.82% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
589.86% | 59.24% | 32.50% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
503.41% | 46.58% | 29.14% | 0.00% | |
Graham Net Nets |
0.11 | 0.07 | 0.05 | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(4.73%) | (4.29%) | (2.83%) | — | |
Free Cash Flow Yield |
(3.56%) | (3.00%) | (2.11%) | — | |
Revenue per Share |
0.03 | 0.35 | 0.66 | 0.00 | |
Operating CF per Share |
(0.79) | (0.91) | (0.55) | (0.78) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.79) | (0.92) | (0.56) | (0.78) | |
Cash per Share |
10.04 | 6.67 | 7.04 | 9.70 | |
Shareholders Equity per Share |
18.70 | 15.79 | 15.37 | 16.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.70 | 15.79 | 15.37 | 16.13 | |
Free Cash Flow |
(66.85) | (89.27) | (54.54) | (78.23) | |
Working Capital |
788.00 | 614.79 | 665.94 | 908.87 | |
Capital Expenditures |
(0.11) | (0.43) | (0.47) | (0.31) | |
Net Current Asset Value |
708.07 | 548.05 | 601.08 | 845.85 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.04 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
— | — | 12.06 | — | |
Average Payables |
5.00 | 11.55 | 7.35 | 8.71 | |
Average Assets |
1,360.42 | 1,293.66 | 1,388.26 | 1,434.66 | |
Average Common Equity |
1,207.64 | 1,162.94 | 1,240.37 | 1,280.39 |
Columns are period end dates · fundamentals updated 2 Nov 2026